|
1
|
Raffoux E, Rousselot P, Poupon J, Daniel
MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, et
al: Combined treatment with arsenic trioxide and all-trans-retinoic
acid in patients with relapsed acute promyelocytic leukemia. J Clin
Oncol. 21:2326–2334. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nitto T and Sawaki K: Molecular mechanisms
of the antileukemia activities of retinoid and arsenic. J Pharmacol
Sci. 126:179–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jing Y and Waxman S: The design of
selective and non-selective combination therapy for acute
promyelocytic leukemia. Curr Top Microbiol Immunol. 313:245–269.
2007.PubMed/NCBI
|
|
4
|
Yan W, Li J, Zhang Y, Yin Y, Cheng Z, Wang
J, Hu G, Liu S, Wang Y, Xu Y, et al: RNF8 is responsible for ATRA
resistance in variant acute promyelocytic leukemia with GTF2I/RARA
fusion, and inhibition of the ubiquitin-proteasome pathway
contributes to the reversion of ATRA resistance. Cancer Cell Int.
19:842019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kopf E, Plassat JL, Vivat V, de The H,
Chambon P and Rochette-Egly C: Dimerization with retinoid X
receptors and phosphorylation modulate the retinoic acid-induced
degradation of retinoic acid receptors alpha and gamma through the
ubiquitin-proteasome pathway. J Biol Chem. 275:33280–33288. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robak P and Robak T: Bortezomib for the
treatment of hematologic malignancies: 15 Years later. Drugs R D.
19:73–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott K, Hayden PJ, Will A, Wheatley K and
Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane
Database Syst Rev. 4:CD0108162016.PubMed/NCBI
|
|
8
|
Yazbeck V, Shafer D, Perkins EB, Coppola
D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, et al:
A phase II trial of bortezomib and vorinostat in mantle cell
lymphoma and diffuse large B-cell lymphoma. Clin Lymphoma Myeloma
Leuk. 18:569–575.e1. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Richardson PG, Oriol A, Beksac M, Liberati
AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T,
et al: Pomalidomide, bortezomib, and dexamethasone for patients
with relapsed or refractory multiple myeloma previously treated
with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3
trial. Lancet Oncol. 20:781–794. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Caravita T, de Fabritiis P, Palumbo A,
Amadori S and Boccadoro M: Bortezomib: Efficacy comparisons in
solid tumors and hematologic malignancies. Nat Clin Pract Oncol.
3:374–387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nencioni A, Grunebach F, Patrone F,
Ballestrero A and Brossart P: Proteasome inhibitors: Antitumor
effects and beyond. Leukemia. 21:30–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roccaro AM, Vacca A and Ribatti D:
Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug
Discov. 1:397–403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang L, Xu L, Xie J, Li S, Guan Y, Zhang
Y, Hou Z, Guo T, Shu X, Wang C, et al: Inhibition of autophagy
overcomes glucocorticoid resistance in lymphoid malignant cells.
Cancer Biol Ther. 16:466–476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu G, Li H, Ji Z, Jiang X, Lei Y and Sun
M: Inhibition of autophagy by autophagic inhibitors enhances
apoptosis induced by bortezomib in non-small cell lung cancer
cells. Biotechnol Lett. 36:1171–1178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Li W, Wang C, Leng X, Lian S,
Feng J, Li J and Wang H: Inhibition of autophagy enhances apoptosis
induced by proteasome inhibitor bortezomib in human glioblastoma
U87 and U251 cells. Mol Cell Biochem. 385:265–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Zhu S, Zhang G and Liu S:
Inhibition of autophagy enhances the anticancer activity of
bortezomib in B-cell acute lymphoblastic leukemia cells. Am J
Cancer Res. 5:639–650. 2015.PubMed/NCBI
|
|
19
|
Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL
and Chen GQ: Arsenic trioxide and proteasome inhibitor bortezomib
synergistically induce apoptosis in leukemic cells: The role of
protein kinase Cdelta. Leukemia. 21:1488–1495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Galluzzi L, Aaronson SA, Abrams J, Alnemri
ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren
K, Borner C, et al: Guidelines for the use and interpretation of
assays for monitoring cell death in higher eukaryotes. Cell Death
Differ. 16:1093–1107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Folkerts H, Hilgendorf S, Vellenga E,
Bremer E and Wiersma VR: The multifaceted role of autophagy in
cancer and the microenvironment. Med Res Rev. 39:517–560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White E: The role for autophagy in cancer.
J Clin Invest. 125:42–46. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Apel A, Zentgraf H, Buchler MW and Herr I:
Autophagy-A double-edged sword in oncology. Int J Cancer.
125:991–995. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eisenberg-Lerner A and Kimchi A: The
paradox of autophagy and its implication in cancer etiology and
therapy. Apoptosis. 14:376–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dalby KN, Tekedereli I, Lopez-Berestein G
and Ozpolat B: Targeting the prodeath and prosurvival functions of
autophagy as novel therapeutic strategies in cancer. Autophagy.
6:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ravikumar B, Sarkar S, Davies JE, Futter
M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M,
Korolchuk VI, Lichtenberg M, Luo S, et al: Regulation of mammalian
autophagy in physiology and pathophysiology. Physiol Rev.
90:1383–1435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Napetschnig J and Wu H: Molecular basis of
NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai Y, Chen S, Wang L, Pei XY, Kramer LB,
Dent P and Grant S: Bortezomib interacts synergistically with
belinostat in human acute myeloid leukaemia and acute lymphoblastic
leukaemia cells in association with perturbations in NF-κB and Bim.
Br J Haematol. 153:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fang J, Rhyasen G, Bolanos L, Rasch C,
Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, et
al: Cytotoxic effects of bortezomib in myelodysplastic
syndrome/acute myeloid leukemia depend on autophagy-mediated
lysosomal degradation of TRAF6 and repression of PSMA1. Blood.
120:858–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Riccioni R, Senese M, Diverio D, Riti V,
Buffolino S, Mariani G, Boe A, Cedrone M, Lo-Coco F, Foà R, et al:
M4 and M5 acute myeloid leukaemias display a high sensitivity to
Bortezomib-mediated apoptosis. Br J Haematol. 139:194–205. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ying M, Zhou X, Zhong L, Lin N, Jing H,
Luo P, Yang X, Song H, Yang B and He Q: Bortezomib sensitizes human
acute myeloid leukemia cells to all-trans-retinoic acid-induced
differentiation by modifying the RARα/STAT1 axis. Mol Cancer Ther.
12:195–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
